ACHV Stock Overview
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom.
Achieve Life Sciences, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.34|
|52 Week High||US$9.42|
|52 Week Low||US$3.25|
|1 Month Change||-28.17%|
|3 Month Change||-31.56%|
|1 Year Change||-61.25%|
|3 Year Change||-88.94%|
|5 Year Change||-99.18%|
|Change since IPO||-99.62%|
Recent News & Updates
Achieve Life Sciences begins phase 2 trial testing cytisinicline for nicotine e-cigarette cessation
Achieve Life Sciences (NASDAQ:ACHV) said it had begun screening subjects in a Phase 2 clinical trial for nicotine e-cigarette cessation. The mid-stage trial, dubbed ORCA-V1, will evaluate the efficacy and safety of 3mg cytisinicline dosed 3 times daily vs. placebo in about 150 adult e-cigarette users at 5 clinical trial locations in the United States. The company's trial is being supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health through grant funding which was awarded in two phases totaling $2.8M.
|ACHV||US Biotechs||US Market|
Return vs Industry: ACHV underperformed the US Biotechs industry which returned -27.4% over the past year.
Return vs Market: ACHV underperformed the US Market which returned -22.1% over the past year.
|ACHV Average Weekly Movement||7.6%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: ACHV is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ACHV's weekly volatility (8%) has been stable over the past year.
About the Company
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol.
Achieve Life Sciences, Inc. Fundamentals Summary
|ACHV fundamental statistics|
Is ACHV overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ACHV income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.29|
|Net Profit Margin||0.00%|
How did ACHV perform over the long term?See historical performance and comparison